These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2129375)

  • 1. The effects of streptokinase and tissue plasminogen activator on left ventricular function.
    White HD
    Adv Exp Med Biol; 1990; 281():383-7. PubMed ID: 2129375
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.
    White HD; Rivers JT; Maslowski AH; Ormiston JA; Takayama M; Hart HH; Sharpe DN; Whitlock RM; Norris RM
    N Engl J Med; 1989 Mar; 320(13):817-21. PubMed ID: 2494454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Streptokinase or tissue plasminogen activator and left ventricular function after myocardial infarction.
    N Engl J Med; 1989 Sep; 321(10):687-9. PubMed ID: 2505074
    [No Abstract]   [Full Text] [Related]  

  • 4. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
    Collen D
    Ann Intern Med; 1990 Apr; 112(7):529-38. PubMed ID: 2107781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The thrombolysis in myocardial infarction (TIMI) trial phase I and phase IIA pilot results. Implications for nursing.
    Brewer-Senerchia C
    Prog Cardiovasc Nurs; 1988; 3(4):128-36. PubMed ID: 2974593
    [No Abstract]   [Full Text] [Related]  

  • 6. Spontaneous hemarthrosis following thrombolytic therapy for acute myocardial infarction.
    Birnbaum Y; Stahl B; Rechavia E
    Int J Cardiol; 1993 Jul; 40(3):289-90. PubMed ID: 8225665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Streptokinase versus recombinant tissue-type plasminogen activator.
    Guharoy SR
    DICP; 1991 Nov; 25(11):1271-2. PubMed ID: 1763549
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
    Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML
    Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
    Lancet; 1995 Aug; 346(8971):329-36. PubMed ID: 7623530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinogen proteolysis and coagulation system activation during thrombolytic therapy.
    Owen J; Grossman B; Sobel J; Kudryk B
    Adv Exp Med Biol; 1990; 281():401-8. PubMed ID: 2129378
    [No Abstract]   [Full Text] [Related]  

  • 11. Thrombolysis in myocardial infarction (TIMI): update 1987.
    Mueller HS
    Klin Wochenschr; 1988; 66 Suppl 12():93-101. PubMed ID: 3126350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A comparative evaluation between streptokinase and r-TPA in limiting the myocardial damage during an acute myocardial infarct. An echocardiographic study].
    Morelloni S; Fasciolo L; Freggiaro V; Corazza M; Pareti G; Davi R; Allegri M
    Clin Ter; 1990 Dec; 135(5):359-65. PubMed ID: 2150366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue-type plasminogen activator for acute coronary thrombosis.
    Med Lett Drugs Ther; 1987 Dec; 29(754):107-9. PubMed ID: 3119965
    [No Abstract]   [Full Text] [Related]  

  • 14. Thrombolytic therapy for MI.
    Rodriguez SW; Reed RL
    Am J Nurs; 1987 May; 87(5):631-40. PubMed ID: 3107386
    [No Abstract]   [Full Text] [Related]  

  • 15. Thrombolysis after myocardial infarction.
    Verstraete M
    Lancet; 1988 Apr; 1(8588):763. PubMed ID: 2895284
    [No Abstract]   [Full Text] [Related]  

  • 16. The rt-PA versus streptokinase controversy--III.
    Sherry S; Marder VJ
    J Am Coll Cardiol; 1992 Apr; 19(5):1119-20. PubMed ID: 1552104
    [No Abstract]   [Full Text] [Related]  

  • 17. Improved left ventricular function in myocardial infarction following intravenous thrombolytic therapy with acylated plasminogen activator.
    Ovsyshcher I; Silber H; Hausman MI; Margolis G; Gueron M
    Angiology; 1990 Feb; 41(2):133-8. PubMed ID: 2407157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rt-PA versus streptokinase controversy--IV.
    Swan HJ
    J Am Coll Cardiol; 1992 Apr; 19(5):1120. PubMed ID: 1552105
    [No Abstract]   [Full Text] [Related]  

  • 19. GISSI-2: mortality plus extensive left-ventricular damage as "end-point".
    De Vita C; Franzosi MG; Geraci E; Maggioni AP; Mauri F; Mezzanotte G; Tavazzi L; Tognoni G; Volpi A
    Lancet; 1990 Feb; 335(8684):289. PubMed ID: 1967740
    [No Abstract]   [Full Text] [Related]  

  • 20. [The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?].
    Negrini M
    G Ital Cardiol; 1995 Apr; 25(4):511-5. PubMed ID: 7677921
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.